U.S. Markets open in 3 hrs 42 mins

Will Veracyte Continue to Surge Higher?

Zacks Equity Research
Novartis (NVS) beats on Q1 earnings, sales marginally miss estimates.

As of late, it has definitely been a great time to be an investor in Veracyte, Inc. VCYT. The stock has moved higher by 25% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.

We certainly think that this might be the case, particularly if you consider VCYT’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as VCYT has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company. You can see the complete list of today’s Zacks #1 Rank stocks here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Veracyte, Inc. (VCYT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research